|
|
$77B Medical Device Giant's CEO Drops $9M on Open-Market Buy |
|
|
Boston Scientific's chief just wrote a personal check for $9 million and bought shares in the open market. No grant. No scheduled buy. Straight cash out of pocket. |
|
|
|
|
Timely AI Shortlist (Sponsored) |
|
|
|
AI is remaking infrastructure, logistics, and automation and a select group of companies sits right in the middle of that shift.
Inside The 10 Best AI Stocks to Own in 2026, one company is building $40K accelerator chips on a full-stack platform designed for wide enterprise adoption.
Another is redefining warehouse automation with a $23B backlog, including all 47 distribution centers of a major U.S. retailer, plus a JV to lease robots to mid-market operators.
From core silicon to industrial robotics, this list highlights AI leaders positioned for long runway growth.
Free access is available for a limited time before it moves behind a paywall. |
Get the 10 Best AI Stocks to Own in 2026 today.
(By clicking the link above, you agree to receive emails from Marketbeat. You can opt out at any time. - Privacy Policy)
|
|
|
|
|
Boston Scientific Corp |
|
|
August 14 – Pre‑market
Ticker: BSX | Sector: Healthcare (Medical Devices) | Market Cap: ~$75.11B |
|
|
|
|
30‑Second Take |
Why now? On August 3, Boston Scientific's Chairman and CEO Michael Mahoney bought 186,240 shares on the open market at $48.33, spending just over $9 million of his own money. |
That's not pocket change. It isn't a routine grant or a scheduled buy either. It's a directional bet from the guy with the best seat in the house. |
The timing lines up too. BSX's Farapulse pulsed-field ablation platform is heading into hypergrowth mode across atrial fibrillation centers, and its Watchman LAA closure device continues to compound double digits YoY. |
If you want a medical device name with a real forward catalyst and an insider putting his own money on the line, this is the setup. |
|
|
Trade Setup |
Time frame: Swing to medium-term (3 to 9 months)
Edge type: Insider signal + product cycle acceleration |
|
|
|
|
|
|
What do you think about most when you're away from markets — on vacation or a weekend? |
|
|
|
|
Snapshot Table |
Metric |
Value |
Current Stance |
Price |
$51.83 |
Just above CEO's $48.33 entry |
52-week range |
$42.20 - $109.50 |
Below average |
Market Cap |
$75.11B |
Large-cap med-tech |
Beta |
0.566 |
Low volatility, defensive tilt |
P/E Ratio |
20.5x (TTM) |
In line with med-tech peers |
Avg Daily Volume |
20.8M shares |
Deep liquidity |
|
|
|
Chart |
|
|
1-Month Synopsis: BSX has been consolidating in a tight band around the CEO's insider buy price. After Mahoney's August 3 purchase at $48.33, shares have drifted up to $51.69, a 7% move on a signal this size. |
The filing hit, the market gave it a polite nod, and shares are still within a few dollars of where the CEO bought. You don't need to chase. |
|
|
Bull Case |
Core thesis: Boston Scientific is a global med-tech leader with two runaway growth engines and a CEO signaling he thinks the stock is cheap. Worth a look. |
Farapulse, its pulsed-field ablation platform, is eating into the atrial fibrillation treatment market. PFA is safer and faster than older thermal ablation methods, and if you look at hospitals, they're switching over as fast as their capital budgets allow. |
This isn't hype. It's real, recurring, high-margin procedure revenue, and BSX is the runaway leader. |
Catalysts: The Watchman left atrial appendage closure device continues to grow double digits year over year. As Medicare expands coverage and cardiologists become more comfortable with the procedure, the addressable patient pool continues to widen. |
You're not paying for a one-trick pony here. |
Then there's the insider signal. Mahoney has been running Boston Scientific since 2012. He knows every product line, every hospital contract, every reimbursement risk. When someone with that much information voluntarily commits $9 million of personal capital at $48.33, the message to you is pretty clear. He thinks the stock is cheap relative to what's coming. |
Studies of insider open-market buys show they precede outperformance more often than not. And this isn't a $50,000 optical purchase. It's nine million dollars. |
Balance sheet cushion: BSX generates strong free cash flow and carries manageable debt. For you, that means the company can keep funding R&D and bolt-on acquisitions without diluting you as a shareholder or stretching leverage. |
In a market where growth stocks trade on hope, you're getting growth backed by real cash. |
|
|
Bear Case |
Here's what could go wrong. You need to know this before you commit any capital. |
Valuation isn't cheap. BSX trades at a premium multiple to the medical device sector. That's fine as long as growth stays double digits. If Farapulse adoption plateaus or a competitor lands a better PFA system, the multiple compresses fast. |
Johnson & Johnson is coming. J&J has its own PFA platform (Varipulse) and is pushing hard on adoption. If they catch up on efficacy data or undercut on price, BSX loses share. |
Reimbursement risk is real too. Any change in Medicare rates for PFA procedures or Watchman implants would directly impact revenue. Not a base case. But not zero either. |
And recalls happen. BSX has had product recalls in the past. One bad safety signal on a lead product and the stock takes a hit. |
Your risk here is a slowing Farapulse ramp or a competitor breakthrough. If either shows up in Q3 numbers, you re-evaluate. Otherwise, the CEO already told you what he thinks. |
|
|
Quick Checklist |
✅ Thesis still valid: CEO insider buy confirmed by SEC filing, PFA cycle intact
✅ Catalyst date double-checked: Q3 results expected late October
✅ Entry near CEO's $48.33 anchor: any pullback is a gift |
|
|
Deep‑Dive Links |
|
|
|
|
That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned! |
Best Regards,
—Noah Zelvis
Everyday Alpha |
|
|
|
|
Everyday Alpha is a publication of Elite Trade Media LLC. |
Disclosure: Content is for informational and entertainment purposes only and is not investment advice. Do not base investment decisions on this newsletter. Securities mentioned may be owned by our owners or operators, which could affect our objectivity. Consult a licensed financial advisor before making any investment decision. We may receive compensation from advertisers and affiliate links in this email, including for featured third-party offers. |
Everyday Alpha and its parent company are not registered investment advisors, broker-dealers, or financial planners. Nothing published by Everyday Alpha — including but not limited to newsletters, emails, text messages, social media posts, or website content — constitutes personalized investment advice, a recommendation to buy or sell any security, or an offer or solicitation to purchase or sell any financial instrument. |
All content is provided strictly for informational and educational purposes. You should not rely on any content published by Everyday Alpha as a substitute for professional financial, legal, or tax advice tailored to your individual circumstances. Always consult a qualified, licensed financial advisor before making any investment decision. |
Forward-Looking Statements: Content may contain forward-looking statements, including projections, opinions, and expectations regarding future events or financial performance. These statements are based on current information and assumptions at the time of writing and are inherently uncertain. Actual results may differ materially. Everyday Alpha is under no obligation to update or revise any forward-looking statement after publication. |
No Guarantee of Accuracy: While Everyday Alpha strives for accuracy, we make no representation or warranty — express or implied — regarding the completeness, reliability, or timeliness of any information provided. Errors, omissions, and outdated information may occur. All content is provided "as is" without warranty of any kind. |
Past Performance: Any reference to past performance of a security, strategy, or index is not indicative of future results. All investments carry risk, including the potential loss of principal. You could lose some or all of your invested capital. |
Editorial Process Disclosure: Everyday Alpha uses proprietary research tools, including AI, in its editorial process. All content is reviewed and approved by our editorial team before publication. Readers should independently verify any information before making financial decisions. |
Advertising & Affiliate Disclosure: Everyday Alpha receives compensation from third-party advertisers and may include paid promotions, sponsored content, and affiliate links within its publications. When you click on certain links or sign up for third-party services featured in our content, we may receive a commission or flat fee. This compensation may influence which companies or products are covered and how they are presented, though it does not affect our editorial opinions. Sponsored content is provided by advertisers and does not represent the views of Everyday Alpha. |
Conflicts of Interest: Contributors, editors, and affiliates of Everyday Alpha may hold positions in securities discussed in our content. These positions may be established or liquidated at any time without notice to readers. |
Limitation of Liability: Under no circumstances shall Everyday Alpha, its owners, employees, affiliates, or contributors be liable for any direct, indirect, incidental, consequential, or punitive damages arising from your use of or reliance on any content published by Everyday Alpha. |
By reading, subscribing to, or otherwise engaging with Everyday Alpha content, you acknowledge and agree to the terms above. |
Update your email preferences or unsubscribe here © 2026 Everyday Alpha 1032 E Brandon Blvd #9644
Brandon, FL 33511, United States |
|
|
|
|
|
|
|
0 التعليقات:
إرسال تعليق